BCLI

|

Brainstorm Cell Therapeutics Inc

NASDAQ

USD 1.13
+0.01|+0.89%

Current Price

USD 1.13

Change

+USD 0.01 (0.89%)

P/E Ratio

Dividend Yield

Market Cap

8.57M

Volume

144,753

Open

USD 1.12

Previous Close

USD 1.12

52-Week High

USD 8.10

52-Week Low

USD 0.72

About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc logo

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance ...

Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Chaim Lebovits
Employees:27
Headquarters:New York, USA

Track BCLI and More with ZuneMoney

Get real-time updates, portfolio tracking, and dividend forecasts.

Dividend History
Dividend Payments
Declared DateRecord DatePayment DateAmountFrequency
Similar Companies
Frequently Asked Questions

Track BCLI and More with ZuneMoney

Get real-time updates, portfolio tracking, and dividend forecasts.